Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s share price dropped 4% during trading on Thursday . The company traded as low as $1.3801 and last traded at $1.43. 1,447,315 shares changed hands during trading, a decline of 5% from the average session volume of 1,521,488 shares. The stock had previously closed at $1.49.
Qualigen Therapeutics Stock Performance
The firm has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.67. The company has a market cap of $2.42 million, a price-to-earnings ratio of -0.19 and a beta of 0.24.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Read More
- Five stocks we like better than Qualigen Therapeutics
- MarketBeat Week in Review – 06/15 – 06/19
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
